Results 51 to 60 of about 5,674 (178)

Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration [PDF]

, 2014
OBJECTIVES: Daclatasvir is a highly potent inhibitor of hepatitis C virus. We estimated the active tissue concentration of daclatasvir in vivo. METHODS: We developed a mathematical model incorporating pharmacokinetic/pharmacodynamic and viral dynamics ...
Sun, Ren, Loverdo, Claude, Lloyd-smith, James O., Qi, Hangfei, Lloyd-Smith, James O, Wu, Nicholas C., Olson, C Anders, Wu, Nicholas C, Olson, C. Anders, Ke, Ruian   +9 more
core   +2 more sources

RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form

Pakistan Journal of Pharmaceutical Sciences, 2021
Daclatasvir dihydrochloride is an antiviral drug used in the treatment of Hepatitis C and for its estimation in drug product, no Pharmacopeial method is available.
Syed Suffdar Hussain Shah, Muhammad Iqbal Nasiri, Humera Sarwar, Aatka Ali, Syed Baqir S Naqvi, Sohail Anwer, Muhammad Kashif   +6 more
doaj   +1 more source

Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder

Pregnancy, Volume 2, Issue 5, September 2026.
Abstract Introduction In the past decade, hepatitis C virus (HCV) infections among pregnant women increased dramatically in the United States, rising in parallel with the opioid crisis and increasing the number of children at risk for HCV. People with HCV infection that remains untreated are also at increased risk of cirrhosis, liver cancer, and death.
Lucas Gosdin, Kathryn Miele, Shin Y. Kim, Marcela C. Smid, Julie H. Shakib, Judette M. Louis, Tanner Wright, Neil S. Seligman, Carrie Irvine, Pilar M. Sanjuan, Lawrence Leeman, Michelle L. Henninger, Autumn Davidson, Elisha M. Wachman, Kara M. Rood, Anna Bartholomew, Suzanne Gilboa, Kate R. Woodworth, Van T. Tong, Lakshmi Panagiotakopoulos   +19 more
wiley   +1 more source

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR

International Journal of Pharmacy & Integrated Health Sciences
Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid ...
Syed Hassan Murtaza, Ahmed Umer Sohaib Ahmed, Tassawer-e-Meran, Sonam Anees, Najam-ul-Hassan Khan, Kishwar Sultana   +5 more
doaj   +1 more source

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region [PDF]

International Journal of Advanced Humanities Research
The liver is the largest organ in the body, located below the diaphragm and protected by the lower ribs of the rib cage (Johns Hopkins Medicine, 2022).
Fahad Alghamdi, Rashed Mohammed
doaj   +1 more source

Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV [PDF]

Advanced Pharmaceutical Bulletin, 2020
Purpose: Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced.
Mohammad Hossein Somi, Bita Sepehri, Zeinab Nikniaz, Roya Sedghi   +3 more
doaj   +1 more source

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 552-562, August 2026.
Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Cyclodextrins as Chiral Selectors in Capillary Electrophoresis—Recent Developments in Understanding Analyte Complexation and Applications in Pharmaceutical Analysis

ELECTROPHORESIS, Volume 47, Issue 8, Page 696-712, August 2026.
Cyclodextrins are the most often applied chiral selectors in CE enantioseparations. In combination with NMR spectroscopy and molecular modeling, studies for an understanding of chiral recognition underlying enantioseparations have been performed.
Gerhard K. E. Scriba
wiley   +1 more source

METHOD DEVELOPMENT AND VALIDATION OF DACLATASVIR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY

, 2018
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active pharmaceutical ingredient(API) form and in ...
CH. V. S Gautam*, N. Harika, V. Balaji, V. Srinivas Prasad
core   +1 more source